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The advent of neurohormonal blockade in heart failure (HF) has been an overwhelming
success, but current evidence points to a ceiling effect as newer neurohormonal targets are
exploited in an incremental manner. This has lead us to question whether the neurohormonal
model of HF can be sustained by simply stacking multiple neurohormonal or cytokine
blockers together as treatment. A unifying theme in some of these disparate trials relates to
either a lack of efficacy or, more importantly, adversity resulting in regression of already
achieved benefits. It is our contention that the available evidence has uncovered the
remarkable complexity of interaction within the context of the neurohormonal construct. As
we stand at a crossroad in HF and begin to fervently pursue non-neurohormonal therapeutic
targets, we must also direct attention at navigating the multifaceted labyrinth of the
neurohormonal model that has led to the current imbroglio. (J Am Coll Cardiol 2003;41:
1606–10) © 2003 by the American College of Cardiology Foundation
Neurohormonal mechanisms that counteract adverse ho-
meostatic imbalance such as salt and water loss evolved as an
important survival trait. Thus, our primal instincts to gather
food by wildlife hunting and survive on dry land without
ready access to salt and water were supported by the creation
of defense systems to ward off deleterious effects emanating
from volume loss. In this regard, the human physiology was
entrained to respond rapidly to an acute or chronic pertur-
bation of the cardiovascular system by implementing salt
and water retention, vasoconstriction, increased heart rate,
and hemostatic mechanisms focused on thrombosis and
eventually tissue repair (1). Heart failure (HF) is a clinical
syndrome characterized by chronic, persistent activation of
the renin-angiotensin-aldosterone system (RAAS) and
sympathetic nervous system (2). In HF, the homeostatic
mechanisms seem activated in response to a perceived
reduction in circulating blood volume. The resultant effect is
the development of a vicious cycle characterized by excessive
neurohormonal stimulation that is responsible not only for
the chronic expression of adverse hemodynamic abnormal-
ities but also myocardial and vascular remodeling, a hall-
mark of progressive HF.
Our recognition of this very tenet has led us to shift
therapy in HF from drugs designed to enhance positive
inotropic status to those designed to halt the progression of
disease (remodeling). It is the latter that favorably influences
survival? The evolution of the era of angiotensin-converting
enzyme (ACE) inhibitors followed by the application of
anti-adrenergic therapies has been more successful than
originally envisioned (3). The success accrued from inhib-
iting two persistently active neurohormonal systems has led
to the proposition that a concerted systematic approach to
inhibit every single errant neurohormonal or cytokine path-
way may continue to provide incremental benefits. How-
ever, recent clinical trial data evaluating this all-
encompassing strategy have yielded startlingly disappointing
results leading us to question whether the neurohormonal
model of HF can be sustained by simply stacking multiple
neurohormonal or cytokine blockers together as treatment.
MORE IS NOT NECESSARILY BETTER
Our suggestion of a neurohormonal threshold of benefit in
HF beyond which “more complete blockade” (as with
higher-dose ACE inhibitors or complimentary angiotensin
receptor antagonism), adjunctive endothelin antagonist use,
cytokine (tumor necrosis factor [TNF]-alpha) blockade, or,
more recently, by the conjoint application of the vasopep-
tidase inhibitor omapatrilat stems from the failure of these
strategies to add incremental value. A unifying theme in
some of these disparate trials relates to either a lack of
efficacy or, more importantly, adversity resulting in regres-
sion of already achieved benefits (Fig. 1).
Is higher-dose ACE inhibition beneficial? The first in-
clination to the phenomenon of a neurohormonal ceiling
emerged with the rather surprising findings from the As-
sessment of Treatment with Lisinopril And Survival (AT-
LAS) trial wherein only modest benefits on morbidity, but
not mortality, were noted when low-dose ACE inhibitors
(lisinopril, 2.5 to 5 mg daily) were compared with high-dose
ACE inhibitors (lisinopril, 35 mg daily) (4). In this trial,
3,164 patients with New York Heart Association (NYHA)
functional class II to IV HF and an ejection fraction 30%
were randomized to double-blind treatment with either low
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doses (2.5 to 5.0 mg daily, n  1,596) or high doses (32.5
to 35 mg daily, n  1568) of the ACE inhibitor lisinopril
for 39 to 58 months, while background therapy for HF was
continued. When compared with the low-dose group,
patients in the high-dose group had a nonsignificant 8%
lower risk of death (p  0.128) but a significant 12% lower
risk of death or hospitalization for any reason (p  0.002)
and 24% fewer hospitalizations for HF (p  0.002).
Dizziness and renal insufficiency was observed more fre-
quently in the high-dose group, but the two groups were
similar in the number of patients requiring discontinuation
of the study medication. Although these data were accrued
before the widespread application of anti-adrenergic ther-
apy, it was viewed with satisfaction that perhaps even
low-dose ACE inhibitors might successfully provide some
degree of benefit and that more robust clinical outcomes
would not necessarily be achieved by pushing ACE inhib-
itors to high doses. A recent study by Nanas et al. (5) that
investigated the use of very high-dose ACE inhibitors
(enalapril, 60 mg daily) compared with standard therapeutic
doses failed to demonstrate significant benefit. In this trial,
no survival benefits were noted in the high-dose ACE
inhibitor group, and the tolerability of this regimen was
limited as evidenced by an excessive withdrawal rate and
poorer compliance. More recently, Tang et al. (6) conducted
a small trial to investigate whether high-dose enalapril (40
mg daily) was better on neurohormonal end points than low
doses of this drug (5 mg daily). Surprisingly, the low-dose
group performed equally well compared with the high-dose
group in suppression of the sentinel neurohormonal param-
eters including angiotensin II, aldosterone, and cat-
echolamines.
Is dual RAAS inhibition better? The addition of angio-
tensin receptor antagonists (ARB) to a stable regimen of
ACE inhibitors and beta-antagonists has also suggested
that this approach may not be warranted. In the Valsartan in
Heart Failure Trial (Val-HeFT), results after a mean
follow-up of 1.89 years indicated that the addition of
valsartan did not affect overall mortality but reduced rehos-
pitalizations for HF (7). Subgroup analyses revealed that the
majority of this benefit was accrued from the group of
patients not taking ACE inhibitors. However, among one-
third of patients receiving triple therapy (ACE inhibitors,
ARBs, and beta-blocker), all-cause morbidity and mortality
demonstrated an unfavorable harmful trend. This important
observation requires verification. Additional data may
emerge from the VALsartan In Acute myocardial iNfarc-
Tion (VALIANT) trial where more than one-half of all
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ACE  angiotensin-converting enzyme
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Figure 1. Saturation of benefits with incremental neurohormonal blockade in chronic heart failure (1975–2003). The curve represents directional tendency
rather than exact point estimates of benefit or adverse outcomes. Spironolactone is not included because the supporting data are from a single large trial
constructed in a distinct population of unstable and severe heart failure patients with low background use of beta-blockers. ACE  angiotensin-converting
enzyme.
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15,000 patients enrolled are receiving so-called “triple ther-
apy.”
Are neutral endopeptidase (NEP) and endothelin antag-
onists useful? Omapatrilat, a vasopeptidase inhibitor, rep-
resents a new class of agents designed to inhibit both the
ACE and NEP, and not only reduces the production of
angiotensin II but also inhibits degradation of bradykinin,
natriuretic, and many other peptides (8); NEP inhibitors
may also increase plasma concentrations of endothelin, a
potentially adverse effect because endothelin is a substrate
for NEP (9). More recently, the Omapatrilat Versus Ena-
lapril Randomized Trial of Utility in Reducing Events
(OVERTURE) HF trial results were reported in 5,770
patients with symptomatic (NYHA functional class II to
IV) systolic HF (left ventricular ejection fraction 0.30)
and a HF hospitalization within the last 12 months (10).
They were all receiving optimal therapies, and 50% were on
beta-blockers, 40% on spironolactone, and 60% on digoxin.
They were then randomized to enalapril (10 mg twice a day)
or omapatrilat (40 mg once daily). The primary end point
(combined risk of death or hospitalization for HF requiring
intravenous treatment) was used prospectively to test both a
superiority and noninferiority hypothesis. The primary end
point fulfilled prespecified criteria for noninferiority but not
for superiority (973 patients in the enalapril group, and 914
patients in the omapatrilat group; hazard ratio, 0.94; p 
0.187). The omapatrilat group also had a 9% lower risk of
cardiovascular death or hospitalization (p  0.024) and a
6% lower risk of death (p  0.339). Adverse effects showed
a higher rate of hypotension and dizziness with omapatrilat.
Angioedema, which has been an issue with omapatrilat in
the treatment of hypertension, was only slightly increased in
the omapatrilat group in this study. The lack of incremental
benefit with omapatrilat may have been due to a resistance
to endogenous natriuretic peptides or to an increase in
hypotension episodes that may have neutralized benefits in
those patients with HF and higher baseline blood pressures.
Additionally, the dose of omapatrilat used may have been
incorrect. Nevertheless, it is troubling that enhancement of
counter-regulatory peptides failed to add benefit (10).
Equally discouraging findings from trials using endothe-
lin antagonists are forthcoming. Two agents, enrasanten
and bosentan, have both failed to demonstrate a significant
benefit in optimally treated systolic HF (11,12). In partic-
ular, the Endothelin Antagonist Bosentan for Lowering
Cardiac Events in Heart Failure (ENABLE) trial evaluated
more than 1,600 patients with severe systolic HF to deter-
mine the effect of this agent on all-cause mortality and HF
hospitalizations. No benefits were observed with this agent,
but the bosentan-treated group had weight gain.
Is excess sympatholysis beneficial or adverse? Inhibition
of the sympathetic nervous system by a centrally acting
sympatholytic agent, moxonidine, was studied in the Mox-
onidine in Congestive Heart Failure (MOXCON) trial in
patients with symptomatic HF (13). The study was termi-
nated early because of higher mortality in the moxonidine
group. A subinvestigation further demonstrated marked
lowering of norepinephrine levels (13). This finding has led
to the suggestion that perhaps the dose of moxonidine
might have been too high, or the titration rate of mox-
onidine was too rapid. Rebound sympathetic activation
between doses may also have occurred, contributing to
increased fatality. In the Beta-blocker Evaluation of Survival
Trial (BEST) study, bucindolol similarly led to a profound
sympatholysis that was associated with excess mortality (14).
Compared with placebo, bucindolol lowered norepineph-
rine by 19% at three months. A surprising nonlinear
relationship effect on prediction of outcome as a function of
plasma norepinephrine levels was observed. Thus, a higher
mortality was noted in those groups that demonstrated
either an increase of norepinephrine over time or a marked
decrease (758 pg/ml). Data such as these point to the
fact that excess sympatholysis may be harmful in the
syndrome of HF.
Is cytokine antagonism useful? In a preliminary investi-
gation of etanercept, a drug that functionally inactivates
TNF-alpha binding sites, improvement in ventricular re-
modeling was noted (15). After three months, a reduction in
left ventricular end-diastolic volumes with small enhance-
ments in ejection fraction were seen, along with improve-
ments in quality of life and clinical scores of HF severity.
These preliminary findings were then used to support
conduction of a large survival study, the Randomized
Etanercept North AmerIcan Strategy to Study ANtagonism
of CytokinEs (RENNAISSANCE) and Research into
Etanercept Cytokine Antagonism and Ventricular Dysfunc-
tion trial (RECOVER). Unfortunately, the RENNAIS-
SANCE trial was stopped prematurely due to a determina-
tion that this trial would not be able to demonstrate efficacy
of this cytokine antagonism approach, and that this strategy
may even be harmful (10). More recently, the combined
results of RECOVER and RENNAISANCE under the
umbrella of the Randomised EtaNErcept Worldwide
evALuation (RENEWAL) trial were presented. The RE-
NEWAL trial combined data on the patients randomized
to placebo or 25 mg of etanercept twice a week from
RECOVER and the patients randomized to placebo, 25 mg
of etanercept twice a week, or 25 mg of etanercept three
times per week from RENAISSANCE. The primary end
point for RENEWAL was the combined morbidity/
mortality end point of death or congestive HF hospitaliza-
tion, and the secondary end point was all-cause mortality. A
trend was seen toward worsening outcomes for the primary
end point in the RENAISSANCE trial (p  0.17), in
which patients were followed for a mean of 12.7 months
after randomization. There was no change from baseline in
patients on treatment, followed for a mean of 5.7 months in
the RECOVER trial. Another TNF-alpha antagonist, in-
fliximab, has also failed to show a benefit in patients with
CHF (16).
Aldosterone antagonists: a glimmer of hope? Spironolac-
tone in nondiuretic doses appears to provide incremental
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benefits to ACE inhibitors. Pitt et al. (17) reported a
convincing benefit on survival, HF hospitalizations, and
symptoms with low-dose spironolactone in severe HF. It
should be noted that this trial was conducted exclusively in
patients with severe HF, few patients received beta-
blockers, and blood pressure was not lowered with this small
dose of spirolnolactone. It is quite possible that spironolac-
tone exerts its sentinel effects by targeting cardiac structural
abnormalities in the extracellular matrix. Zannad et al. (18)
studied the effects of spironolactone on markers of cardiac
fibrosis and suggested that high baseline serum levels of
markers of cardiac fibrosis synthesis were significantly asso-
ciated with poor outcome and were decreased during spi-
ronolactone therapy. The benefit from spironolactone was
confined in patients with higher levels of collagen turnover.
The results suggest that limitation of the excessive extracel-
lular matrix turnover may be one of the various extra renal
mechanisms contributing to the beneficial effect of spirono-
lactone in patients with HF.
EMERGING THERAPEUTIC TARGETS
As the totality of current evidence suggests a limit to
multiple neurohormonal blocking drugs to treat HF, it is
important for us to derive other therapeutic strategies in an
effort to incrementally influence morbidity and mortality in
HF. These specific strategies include modulation of myo-
cardial metabolic substrate utilization, alleviation of myo-
cardial ischemia, and relief of arrhythmic burden. Other
novel areas of investigation relate to identifying and treating
sleep disordered breathing, amelioration of anemia and
renal dysfunction, and resynchronization of contraction
as well as use of other anti-remodeling devices (19 –34)
(Fig. 2).
CONCLUSIONS
In summary, the advent of neurohormonal blockade in HF
has been an overwhelming success, but current evidence
points to a ceiling effect. Pharmacotherapy designed to
block the RAAS has served us well, and, save for a few
notable non-successes, so have adrenergic inhibitors. Do the
current data signal demise of the neurohormonal model
with regard to stack-on blockade beyond RAAS and adren-
ergic targets? It is our contention that the available
evidence has uncovered the remarkable complexity of
interaction within the context of the neurohormonal
construct. As we stand at a crossroad in HF and begin to
fervently pursue non-neurohormonal therapeutic targets,
we must also direct attention at navigating the multifac-
eted labyrinth of the neurohormonal model that has led
to the current imbroglio.
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Figure 2. Potential therapeutic targets beyond the neurohormonal model. Emerging investigations are focusing on amelioration of wall stress by using
surgical remodeling and resynchronization therapy. Other important strategies are tackling myocardial metabolism, ischemia abrogation, sudden death
prevention, anemia, sleep disorders, and renal insufficiency in heart failure.
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